tinzaparin


Also found in: Wikipedia.

tinzaparin

 [tin-zap´ah-rin]
a low-molecular-weight heparin obtained by depolymerization of heparin from porcine intestinal mucosa using a bacterial enzyme; it acts as an anticoagulant and antithrombotic and is used as an adjunct to warfarin in the treatment of deep venous thrombosis with or without pulmonary embolism, administered subcutaneously.

tinzaparin

/tin·zap·a·rin/ (tin-zap´ah-rin) a low-molecular-weight heparin of porcine origin, having antithrombotic activity and used with warfarin in the treatment of deep venous thrombosis with or without pulmonary embolism.

tinzaparin

[tin-zap′ah-rin]
a low-molecular-weight heparin obtained by depolymerization of heparin from porcine intestinal mucosa by using a bacterial enzyme. It acts as an anticoagulant and antithrombotic and is used as an adjunct to warfarin in the treatment of deep venous thrombosis with or without pulmonary embolism and is administered subcutaneously.

tinzaparin

Innohep® Vascular disease An LMW heparin for preventing and treating DVT, PTE. See Low-molecular weight heparin.

tinzaparin

A LOW MOLECULAR WEIGHT HEPARIN drug that interferes with the action of Factor Xa in the blood coagulation cascade and can be used to prevent blood clotting within the blood vessels in people undergoing surgery. A brand name is Innohep.
References in periodicals archive ?
Voluntary ex ante transparency notice: Supply of Tinzaparin (Innohep) in a range of presentations to health boards across NHS Scotland.
Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial.
Specifically, subcutaneous LMWH (enoxaparin [Lovenox[R]], dalteparin [Fragmin[R]], and tinzaparin [Innohep[R]]) is considered better than intravenous, continuous UFH; the latter is preferred only in patients with complicating factors such as renal insufficiency.
Other well-studied LMWHs include dalteparin and tinzaparin.
Methods: In this prospective observational study 150 women with a history of two or more previous unexplained first trimester pregnancy loss who received LMWH; either enoxaparin (n=50) tinzaparin (n=50) or nothing (n=50) were followed for the pregnancy outcome measures.
Relationship Between Baseline Blood Pressure Parameters (Including Mean Pressure, Pulse Pressure, and Variability) and Early Outcome After Stroke: Data From the Tinzaparin in Acute Ischaemic Stroke Trial (TAIST).
56) including 100 UC cases with mild or moderate activity, tlicy reported that tinzaparin was not superior to placebo.
Actually, she also happened to receive tinzaparin, a low molecular weight (LMW) heparin, during days 20 to 23 as prophylaxis for deep vein thrombosis (DVT).
President and CEO of PolyMedix Nicholas Landekic said that in previous studies PMX-60056 had met the safety and efficacy endpoints in reversing the anticoagulant activity of unfractionated heparin and the low molecular weight heparin, tinzaparin.
In all subjects receiving the drug, there was a rapid reduction in anti-Xa activity, a measurement of LMWH action, and a rapid and complete reversal of the anticoagulant action of tinzaparin, a specific form of LMWH.
Several types of LMWH are commonly used including enoxaparin (Clexane[R], Rhone-Poulenc Rorer), dalteparin (Fragmin[R], Pharmacia) and tinzaparin (Innohep[R], LEO), with bleeding and thrombocytopenia having been known complications (BNF 2008).